NDA 020726 · Novartis Pharms
Femara
Letrozole · Oral · Aromatase Inhibitor
NovelAccelerated approvalLast checked: Nov 20, 2026Latest source record: Dec 16, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1997
Jul 25, 1997
Approved uses
9
Original approval plus efficacy supplements
Registered trials
818
198 Phase 3, 130 recruiting
FAERS reports
62,445
50,509 serious, 6,134 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 11, 2026.
Femara is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. ( 1.1 ) Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy. ( 1.2 ) First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer. ( 1.3 ) 1.1 Adjuvant Treatment of Early Breast Cancer Femara (letrozole) is indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. 1.2 Extended Adjuvant Treatment of Early Breast Cancer Femara is indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. The effectiveness of Femara in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival (DFS) in patients treated with Femara for a median of 60 months [see Clinical Studies (14.2, 14.3)] . 1.3 First and Second-Line Treatment of Advanced Breast Cancer Femara is indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. Femara is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy [see Clinical Studies (14.4, 14.5)].
Mechanism: The growth of some cancers of the breast is stimulated or maintained by estrogens. Treatment of breast cancer thought to be hormonally responsive (i.e., estrogen and/or progesterone receptor positive or receptor unknown) has included a variety of efforts to decrease estrogen levels (ovariectomy, adrenalectomy, hypophysectomy) or inhibit estrogen effects (antiestrogens and progestational agents). These interventions lead to decreased tumor mass or delayed progression of tumor growth in some women. In postmenopausal women, estrogens are mainly derived from the action of the aromatase enzyme,...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 30, 2010 Supplement 20 · Efficacy LetterLabel
- Mar 2, 2010 Supplement 16 · Efficacy LabelLetter
- Mar 2, 2010 Supplement 15 · Efficacy LabelLetter
- Dec 28, 2005 Supplement 12 · Efficacy · priority review LabelLetter
- Oct 29, 2004 Supplement 11 · Efficacy LabelLetter
- Feb 26, 2003 Supplement 5 · Efficacy LabelLetter
- Jan 17, 2003 Supplement 8 · Efficacy LetterLabel
- Jan 10, 2001 Supplement 6 · Efficacy · priority review LabelReviewLetter
- Jul 25, 1997 Original approval · Type 1 - New Molecular Entity Review
1 products under this application
- FEMARA · LETROZOLE 2.5MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Letrozole" as an intervention, any sponsor and status, largest first.
- Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)Pivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT00310180 · 10,273 participants · Start Apr 7, 2006 · Primary completion Mar 2, 2018
Drug: Anastrozole; Exemestane and 2 more · For: Breast Adenocarcinoma; Hormone Receptor Positive; Stage IA Breast Cancer AJCC v7 and 4 more
Sites: Anniston, Alabama; Birmingham, Alabama; Mobile, Alabama · 1,222 sites in all
- Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast CancerPivotal-lookingCompleted
ETOP IBCSG Partners FoundationResearch network
NCT00004205 · 8,028 participants · Start Mar 1998 · Primary completion Dec 2008
Drug: letrozole; tamoxifen citrate · For: Breast Cancer
Sites: Copenhagen, Denmark; Bordeaux, France; Sankt Gallen, Switzerland
- A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast CancerPivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT05514054 · 8,000 participants (planned) · Start Oct 4, 2022 · Primary completion Oct 2027
Drug: Imlunestrant; Tamoxifen and 3 more · For: Breast Neoplasms
Sites: Daphne, Alabama; Huntsville, Alabama; Mobile, Alabama · 672 sites in all
- Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph NodesPivotal-lookingCompleted
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT00433589 · 6,600 participants (planned) · Start Feb 2007 · Primary completion Mar 2020
Drug: anthracycline-based; docetaxel and capecitabine and 2 more · For: Breast Cancer
Sites: Amsterdam, Netherlands
- An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)Pivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT05952557 · 5,511 participants · Start Oct 5, 2023 · Primary completion Mar 4, 2030
Drug: Camizestrant; Tamoxifen and 4 more · For: Breast Cancer, Early Breast Cancer
Sites: Dothan, Alabama; Phoenix, Arizona; Tucson, Arizona · 661 sites in all
- A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast CancerPivotal-lookingRecruiting
Shandong Suncadia Medicine Co., Ltd.Industry
NCT07349069 · 5,500 participants (planned) · Start Mar 4, 2026 · Primary completion Dec 2030
Drug: HRS-8080 Tablets; Letrozole tablets and 3 more · For: Breast Cancer
Sites: Nanjing, China; Shanghai, China
- Letrozole After Tamoxifen in Treating Women With Breast CancerPivotal-lookingCompleted
NCIC Clinical Trials GroupResearch network
NCT00003140 · 5,187 participants · Start Aug 24, 1998 · Primary completion Aug 22, 2003
Drug: letrozole · For: Breast Cancer
Sites: Lethbridge, Canada; Kelowna, Canada; Nanaimo, Canada · 57 sites in all
- A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast CancerPivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT03701334 · 5,101 participants · Start Dec 7, 2018 · Primary completion May 29, 2030
Drug: Ribociclib · For: Early Breast Cancer
Sites: Birmingham, Alabama; Goodyear, Arizona; Jonesboro, Arkansas · 387 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue7,561
- nausea5,594
- neutropenia5,295
- diarrhoea4,792
- malignant neoplasm progression4,614
- arthralgia4,046
- white blood cell count decreased3,845
- alopecia3,711
- pain3,097
- asthenia3,034
- dyspnoea2,976
- vomiting2,820
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 155 |
| 2005 | 305 |
| 2006 | 463 |
| 2007 | 438 |
| 2008 | 515 |
| 2009 | 606 |
| 2010 | 934 |
| 2011 | 1,099 |
| 2012 | 1,083 |
| 2013 | 869 |
| 2014 | 827 |
| 2015 | 1,937 |
| 2016 | 3,080 |
| 2017 | 3,344 |
| 2018 | 4,475 |
| 2019 | 5,738 |
| 2020 | 5,880 |
| 2021 | 6,044 |
| 2022 | 5,875 |
| 2023 | 5,949 |
| 2024 | 5,025 |
| 2025 | 4,538 |
| 2026 | 3,266 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Femara (Letrozole)
2024 spending
$1.3M
Beneficiaries
208
905 claims
Per beneficiary
$6,302
$25.03 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,352,001 |
| 2021 | $1,950,059 |
| 2022 | $1,556,773 |
| 2023 | $1,465,126 |
| 2024 | $1,310,720 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Palbociclib and Letrozole in Advanced Breast Cancer.
Finn RS, Martin M, Rugo HS, et al. · N Engl J Med 2016 · Clinical Trial, Phase III, Multicenter Study
- Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Hortobagyi GN, Stemmer SM, Burris HA, et al. · Ann Oncol 2018 · Clinical Trial, Phase III, Multicenter Study
- Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
Hortobagyi GN, Stemmer SM, Burris HA, et al. · N Engl J Med 2022 · Clinical Trial, Phase III, Comparative Study
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
Hortobagyi GN, Stemmer SM, Burris HA, et al. · N Engl J Med 2016 · Clinical Trial, Phase III, Multicenter Study
- Letrozole versus clomiphene for infertility in the polycystic ovary syndrome.
Legro RS, Brzyski RG, Diamond MP, et al. · N Engl J Med 2014 · Comparative Study, Multicenter Study
- Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer.
Slamon DJ, Diéras V, Rugo HS, et al. · J Clin Oncol 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.